

Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing. U.S. Venture Partners led the round.
Source: Press Release
Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing.
Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing. U.S. Venture Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination